Brief: Ocuphire Pharma Enters Into License Agreement For Development And Commercialization Of Nyxol Eye Drops
07/11/2022 22:30
Nov 7 (Reuters) - Ocuphire Pharma Inc OCUP.O :
* OCUPHIRE PHARMA ENTERS INTO A GLOBAL LICENSE AGREEMENT FOR
DEVELOPMENT AND COMMERCIALIZATION OF NYXOL EYE DROPS FOR
REVERSAL OF MYDRIASIS, PRESBYOPIA AND NIGHT VISION DISTURBANCES
* OCUPHIRE PHARMA INC- TO RECEIVE $35 MILLION UPFRONT, NYXOL
DEVELOPMENT FUNDING AND ADDITIONAL POTENTIAL MILESTONE PAYMENTS
PLUS TIERED DOUBLE-DIGIT ROYALTIES
* OCUPHIRE PHARMA INC- STRENGTHENED FINANCIAL POSITION
SUPPORTS
OPERATIONS AND APX3330 PROGRAM INTO 2025
Source text for Eikon: ID:nGNXbgkb8Q
Further company coverage: OCUP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data